In addition, the extreme genetic heterogeneity in NPH-related ciliopathies, i.e., the absence of mutation hot spots except for the homozygous NPHP1 deletion, and possible role of modifier variants, limit the practical and financial feasibility of gene-targeted therapies (Kim and Kim, 2019). This evidence concerns the gene NPHP1 and ciliopathy.